Imidazole-containing condensed ring derivative, preparation method therefor, and application thereof in medicine
US-2024228501-A1 · Jul 11, 2024 · US
Aminotriazolopyridine for use in the treatment of inflammation, and pharmaceutical compositions thereof
US9284311B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9284311-B2 |
| Application number | US-201313913597-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 10, 2013 |
| Priority date | Jun 22, 2012 |
| Publication date | Mar 15, 2016 |
| Grant date | Mar 15, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to the compound according to Formula I, and to its use in medicine, in particular in the treatment of inflammatory conditions, autoimmune diseases, proliferative diseases, allergy, transplant rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 or interferons. In particular, the compound inhibits JAK a family of tyrosine kinases, and more particularly JAK1. The present invention also provides pharmaceutical compositions comprising the compound, methods for the prophylaxis and/or treatment of diseases involving inflammatory conditions, autoimmune diseases, proliferative diseases, allergy, transplant rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 or interferons by administering the compound.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method for the treatment of a mammal afflicted with rheumatoid arthritis, which method comprises administering a therapeutically effective amount of a compound according to Formula I: 2. The method according to claim 1 , wherein the said compound is administered in combination with one or more additional therapeutic agents, wherein said additional therapeutic agent is a rheumatoid arthritis treating agent. 3. The method according to claim 2 , wherein the additional therapeutic agent is according to Formula II: 4. The method according to claim 3 , wherein the ratio of Formula I/Formula II is from 1/5 to 1/20. 5. The method according to claim 3 , wherein the ratio of Formula I/Formula II is from 1/5 to 1/10. 6. The method according to claim 1 , wherein the mammal is a human.
Assignees
Inventors
Classifications
Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14) · CPC title
Immunosuppressants, e.g. drugs for graft rejection · CPC title
Antineoplastic agents · CPC title
Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title
Drugs for immunological or allergic disorders · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9284311B2 cover?
- The present invention relates to the compound according to Formula I, and to its use in medicine, in particular in the treatment of inflammatory conditions, autoimmune diseases, proliferative diseases, allergy, transplant rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and/or diseases associated with hypersecretion of IL6 or interferons. In pa…
- Who is the assignee on this patent?
- Van T Klooster Gerben Albert Eleutherius, Namour Florence Sylvie, Brys Réginald Christophe Xavier, and 2 more
- What technology area does this patent fall under?
- Primary CPC classification A61K31/541. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Mar 15 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).